PUBLICATIONS

Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim HG, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T.

An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.

Cell 183: 1-16, 2020.


Saito Y, Muramatsu T, Saito H.

Establishment and Long-Term Culture of Organoids Derived from Human Biliary Tract Carcinoma.

STAR Protocols 1(1): 100009, 2020.


Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H. 

Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. 

Cell Reports 27(4): 1265-1276, 2019. 


Katsuda T, Matsuzaki J, Yamaguchi T, Yamada Y, Prieto-Vila M, Hosaka K, Takeuchi A, Saito Y, Ochiya T. 

Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes. 

Elife 8. pii: e47313, 2019.


Lau DK, Mouradov D, Wasenang W, Luk IY, Scott CM, Williams DS, Yeung YH, Limpaiboon T, Iatropoulos GF, Jenkins LJ, Reehorst CM, Chionh F, Nikfarjam M, Croagh D, Dhillon AS, Weickhardt AJ, Muramatsu T, Saito Y, Tebbutt NC, Sieber OM, Mariadason JM. 

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. 

iScience 21: 624-637, 2019.


Saito Y. 

Establishment of an organoid bank of biliary tract and pancreatic cancers and its application for personalized therapy and future treatment. 

Journal of Gastroenterology and Hepatology 34(11): 1906-1910, 2019.


Yoshikawa N, Saito Y, Manabe H, Nakaoka T, Uchida R, Furukawa R, Muramatsu T, Sugiyama Y, Kimura M, Saito H.

Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through AKT Phosphorylation and Reactive Oxygen Species. 

Cancers 11(12). pii: E1993, 2019.


Uchida R, Saito Y, Nogami K, Kajiyama Y, Suzuki Y, Kawase Y, Nakaoka T, Muramatsu T, Kimura M, Saito H. 

Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging. 

npj Aging and Mechanisms of Disease 5, 2019. 


Chuma M, Toyoda H, Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Tanaka K, Maeda S, Sakamoto N. 

Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. 

Hepatology Research 49(7): 810-822, 2019.


Yamaguchi T, Matsuzaki J, Katsuda T, Saito Y, Saito H, Ochiya T. 

Generation of functional human hepatocytes in vitro: current status and future prospects. 

Inflammation and Regeneration 39: 13, 2019.


Saito Y, Konno K, Sato M, Nakano M, Kato Y, Saito H, Serizawa H. 

Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori.

Cancers 11(1): pii: E116, 2019. 


Saito Y, Nakaoka T, Muramatsu T, Ojima H, Sukeda A, Sugiyama Y, Uchida R, Furukawa R, Kitahara A, Sato T, Kanai Y, Saito H. 

Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. 

Scientific Reports 8(1): 2821, 2018. 


Saito Y, Saito H. 

Epigenetics and aging. 

Glycative Stress Research 5(3): 129-134, 2018. 


Tsugawa H, Mori H, Matsuzaki J, Sato A, Saito Y, Imoto M, Suematsu M, Suzuki H. 

CAPZA1 determines the risk of gastric carcinogenesis by inhibiting Helicobacter pylori CagA-degraded autophagy.

Autophagy 10: 1-17, 2018. 


Yamada S, Kimura M, Saito Y, Saito H. 

Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. 

Journal of Clinical Biochemistry and Nutrition 63(2): 123-128, 2018.


Murakami Y, Sugiyama K, Ebinuma H, Nakamoto N, Ojiro K, Chu PS, Taniki N, Saito Y, Teratani T, Koda Y, Suzuki T, Saito K, Fukasawa M, Ikeda M, Kato N, Kanai T, Saito H. 

Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells. 

BMC Cancer 18(1): 680, 2018. 


Yamada S, Takashina Y, Watanabe M, Nagamine R, Saito Y, Kamada N, Saito H. 

Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. 

Oncotarget 9(11): 9925-9939, 2018. 


Shibata S, Matsushita M, Saito Y, Suzuki T. 

Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan.

Therapeutic Innovation & Regulatory Science 52(4): 442-448, 2018.


Shibata S, Matsushita M, Saito Y, Suzuki T. 

Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy. 

Therapeutic Innovation & Regulatory Science 52(6): 718-723, 2018. 


Nakaoka T, Saito Y, Shimamoto Y, Muramatsu T, Kimura M, Kanai Y, Saito H. 

Cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids. 

Cancer Science 108(4): 678-684, 2017. 


Nakaoka T, Saito Y, Saito H. 

Aberrant DNA methylation as a biomarker and a therapeutic target of cholangiocarcinoma. 

International Journal of Molecular Sciences 18(6): 1111, 2017.


Saito Y, Nakaoka T, Saito H. 

A new molecular mechanism underlying the antitumor effect of DNA methylation inhibitors via an antiviral immune response. 

Advances in Protein Chemistry and Structural Biology 106: 227-242, 2017.


Yamada S, Kamada N, Amiya T, Nakamoto N, Nakaoka T, Kimura M, Saito Y, Ejima C, Kanai T, Saito H. 

Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis. 

BMC Gastroenterology 17(1): 136, 2017. 


Saito Y, Nakaoka T, Sakai K, Muramatsu T, Toshimitsu K, Kimura M, Kanai T, Sato T, Saito H. 

Inhibition of DNA Methylation Suppresses Intestinal Tumor Organoids by Inducing an Anti-Viral Response. 

Scientific Reports 6: 25311, 2016. 


Ueki S, Murakami Y, Yamada S, Kimura M, Saito Y, Saito H. 

microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line. 

BMC Cancer 16(1): 732, 2016. 


Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. 

First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. 

World Journal of Gastroenterology 21(48): 13548-13554, 2015. 


Saito Y, Nakaoka T, Saito H. 

microRNA-34a as a therapeutic agent against human cancer. 

Journal of Clinical Medicine 4(11): 1951-1959, 2015. 


Saito Y, Saito H, Liang G, Friedman JM. 

Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review. 

Clinical Reviews in Allergy & Immunology 47(2): 128-35, 2014. 


Saito Y. 

Alterations of epigenetics and microRNAs in cancer and cancer stem cell. 

Frontiers in Genetics 5: 283, 2014. 


Saito Y, Hibino S, Saito H. 

Alterations of epigenetics and microRNAs in hepatocellular carcinoma. 

Hepatology Research 44(1): 31-42, 2014. 


Kimura M, Iida M, Yamauchi H, Suzuki M, Shibasaki T, Saito Y, Saito H. 

Astaxanthin supplementation effects on adipocyte size and lipid profile in OLETF rats with hyperphagia and visceral fat accumulation. 

Journal of Functional Foods 11: 114-120, 2014. 


Sugiyama K, Ebinuma H, Nakamoto N, Sakasegawa N, Murakami Y, Chu PS, Usui S, Ishibashi Y, Wakayama Y, Taniki N, Murata H, Saito Y, Fukasawa M, Saito K, Yamagishi Y, Wakita T, Takaku H, Hibi T, Saito H, Kanai T. 

Prominent steatosis with hypermetabolism of the cell line permissive for years of infection with hepatitis C virus. 

PLoS One 9(4): e94460, 2014. 


Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H. 

Inhibitors of enhancer of zeste homologue 2 (EZH2) activate tumor suppressor microRNAs in human cancer cells.

Oncogenesis 3: e104, 2014. 


Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, Muramatsu T, Kimura M, Sugiyama K, Suzuki H, Arai E, Ojima H, Kanai Y, Saito H. 

Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. 

Cancer Science 105(10): 1254-60, 2014. 


Matsuzaki J, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E, Saito Y, Sekine S, Akaike T, Kanai Y, Mukaisho K, Auwerx J, Hibi T.

Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis.

Gastroenterology 145(6): 1300-11, 2013.


Sugiishi A, Kimura M, Kamiya R, Ueki S, Yoneya M, Saito Y, Saito H. 

Derangement of ghrelin secretion after long-term high-fat diet feeding in rats. 

Hepatology Research 43(10):1105-14, 2013. 


Sato A, Saito Y, Sugiyama K, Sakasegawa N, Muramatsu T, Fukuda S, Yoneya M, Kimura M, Ebinuma H, Hibi T, Saito H.

Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells. 

Journal of Cellular Biochemistry 114(9): 1987-96, 2013. 


Saito Y, Suzuki H, Imaeda H, Matsuzaki J, Hirata K, Tsugawa H, Hibino S, Kanai Y, Saito H, Hibi T. 

The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.

International Journal of Cancer 132(8): 1751-60, 2013. 


Saito Y, Saito H. 

MicroRNAs in cancers and neurodegenerative disorders. 

Frontiers in Genetics 3: 194, 2012.


Saito Y, Saito H. 

Role of CTCF in the regulation of microRNA expression. 

Frontiers in Genetics 3: 186, 2012. 


Inaba N, Kimura M, Fujioka K, Ikeda K, Somura H, Akiyoshi K, Inoue Y, Nomura M, Saito Y, Saito H, Manome Y. 

The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells. 

Anticancer Research 31(5): 1653-8, 2011. 


Saito Y, Suzuki H, Matsuura M, Sato A, Kasai Y, Yamada K, Saito H, Hibi T. 

MicroRNAs in hepatobiliary and pancreatic cancers. 

Frontiers in Genetics 2: 66, 2011.